Clinsys Clinical Researchannounced the launch of Clinsys ALTERNA for customized Phase I–IV alternative solutions.
Bedminster, NJ-April 10, 2008-Clinsys Clinical Research, a therapeutically focused global contract research organization, today announced the launch of Clinsys ALTERNA, which utilizes its Global Project Solution® (Clinsys GPS®) to augment clinical resource services. The new division demonstrates Clinsys’ commitment to aligning its service offerings with its sponsors’ and the life sciences industry’s continuously evolving staffing needs.
Clinsys ALTERNA provides customized Phase I–IV clinical trial alternative solutions to the conventional outsourcing model. The division is a core element of Clinsys GPS, a unique, highly effective, and proven integrated project management solution that brings the sponsor and the Clinsys project teams together to collaborate and agree on all aspects of the clinical study-before, during, and after-to ensure the project’s success.
“Clinsys ALTERNA provides a targeted and flexible clinical resourcing model that adapts to best serve a sponsor’s trial management needs,” said David E. Williams, chief executive officer of Clinsys. “We devoted the time and energy required to approach the evolution of resourcing in an innovative way that both maximizes efficiencies and decreases deliverable timelines.”
Drawing on extensive clinical research experience, Clinsys ALTERNA delivers a custom-designed, time-sensitive clinical solution that enables sponsors to engage its services in site management, clinical monitoring, project management, drug safety, regulatory, and medical writing on a contract basis. Clinsys ALTERNA combines therapeutic expertise, clinical screening, performance reviews, site references, and global reach to offer clients the most dependable and comprehensive alternative approach to their trial needs. Visit clinsysalterna.com for more information.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.